Small Molecule Therapeutic Discovery for Angelman Syndrome
天使综合症的小分子治疗发现
基本信息
- 批准号:10636253
- 负责人:
- 金额:$ 57.55万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-06-01 至 2028-05-31
- 项目状态:未结题
- 来源:
- 关键词:AllelesAnatomyAngelman SyndromeAntisense OligonucleotidesBehavioralBiodistributionBiological AvailabilityBiologyBiotinylationBrainCDK2 geneCellsChemistryClinicClinicalClinical TrialsDataDevelopmentDoseElectrophysiology (science)Epigenetic ProcessFailureFutureHumanIndividualIntrathecal InjectionsLifeMusMutationNeurodevelopmental DisorderNeuronsPeripheralPharmaceutical PreparationsPharmacologyPhenotypePhysiologicalPropertyProteinsRegimenResearchSourceStructure-Activity RelationshipSurveysTestingTherapeuticTopoisomeraseTopoisomerase InhibitorsTopotecanToxic effectTranscriptUBE3A geneUntranslated RNAWorkanalogautism spectrum disorderblood-brain barrier penetrationcomorbidityeffective therapyenantiomerexperimental studyimprovedinhibitorinsightlead candidatemouse modelnovelpatient populationpharmacokinetics and pharmacodynamicspostnatalprotein expressionsafety studyscreeningsmall moleculesmall molecule therapeuticsstem cellstherapeutic targetubiquitin-protein ligase
项目摘要
PROJECT SUMMARY
Angelman syndrome is a severe neurodevelopmental disorder caused by maternal allele deletions of UBE3A.
In neurons, the paternal allele of UBE3A is epigenetically silenced. Unsilencing the paternal allele of UBE3A
offers a potentially transformative opportunity for treating Angelman syndrome. We recently discovered a small
molecule that unsilences the paternal allele of UBE3A in neurons cultured from Angelman syndrome model
mice or from stem cells derived from Angelman syndrome individuals. When delivered noninvasively to
Angelman syndrome model mice, this small molecule leads to brain-wide neuronal UBE3A protein expression
without observable toxicity. We hypothesize that our small molecule approach can reverse Angelman
syndrome phenotypes in mice, justifying its advance towards additional safety studies and future clinical trials.
Towards developing this approach as a non-invasive treatment for Angelman syndrome, we propose to (1)
establish rescue of behavioral and electrophysiological phenotypes in Angelman syndrome model mice, (2)
identify the mechanism of action by which our small molecule produces unsilencing of paternal UBE3A, and (3)
perform structure-activity-relationship studies to improve efficacy and maximize favorable pharmacology. By
advancing the first small molecule treatment of Angelman syndrome, this research may lead to therapy yielding
profound lifelong benefits for this patient population.
项目摘要
Angelman综合征是一种严重的神经发育障碍,由UBE3A的母体等位基因缺失引起。
在神经元中,UBE3A的父系等位基因在表观遗传学上是沉默的。解除UBE3A父系等位基因的沉默
为治疗安格尔曼综合征提供了一个潜在的变革机会。我们最近发现了一个小的
在Angelman综合征模型培养的神经元中使UBE 3A的父系等位基因不沉默的分子
小鼠或源自Angelman综合征个体的干细胞。当非侵入性地输送到
Angelman综合征模型小鼠,这种小分子导致全脑神经元UBE 3A蛋白表达
没有明显的毒性。我们假设我们的小分子方法可以逆转Angelman
在小鼠中的综合征表型,证明其对额外的安全性研究和未来的临床试验的进展。
为了发展这种方法作为一种非侵入性治疗Angelman综合征,我们建议(1)
在Angelman综合征模型小鼠中建立行为和电生理表型拯救,(2)
确定我们的小分子产生父本UBE 3A非沉默的作用机制,以及(3)
进行构效关系研究,以提高疗效并最大限度地发挥有利的药理作用。通过
这项研究推进了Angelman综合征的第一个小分子治疗,
对这一患者群体有着深远的终身益处。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jeffrey Aube其他文献
Jeffrey Aube的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jeffrey Aube', 18)}}的其他基金
Discovery of Phospopantetheinyl Transferse Inhibitors Against Mycobacterium tuberculosis
抗结核分枝杆菌磷酸泛酰基转移酶抑制剂的发现
- 批准号:
10450109 - 财政年份:2021
- 资助金额:
$ 57.55万 - 项目类别:
UNC Chemical Biology Interface Training Program
北卡罗来纳大学化学生物学界面培训计划
- 批准号:
10646465 - 财政年份:2021
- 资助金额:
$ 57.55万 - 项目类别:
Discovery of Phospopantetheinyl Transferse Inhibitors Against Mycobacterium tuberculosis
抗结核分枝杆菌磷酸泛酰基转移酶抑制剂的发现
- 批准号:
10653027 - 财政年份:2021
- 资助金额:
$ 57.55万 - 项目类别:
Discovery of Phospopantetheinyl Transferse Inhibitors Against Mycobacterium tuberculosis
抗结核分枝杆菌磷酸泛酰基转移酶抑制剂的发现
- 批准号:
10298705 - 财政年份:2021
- 资助金额:
$ 57.55万 - 项目类别:
UNC Chemical Biology Interface Training Program
北卡罗来纳大学化学生物学界面培训计划
- 批准号:
10089153 - 财政年份:2021
- 资助金额:
$ 57.55万 - 项目类别:
UNC Chemical Biology Interface Training Program
北卡罗来纳大学化学生物学界面培训计划
- 批准号:
10415825 - 财政年份:2021
- 资助金额:
$ 57.55万 - 项目类别:
Novel Probes of the Kappa Opioid Receptor: Chemistry, Pharmacology, and Biology
Kappa 阿片受体的新型探针:化学、药理学和生物学
- 批准号:
9889913 - 财政年份:2016
- 资助金额:
$ 57.55万 - 项目类别:
Novel Probes of the Kappa Opioid Receptor: Chemistry, Pharmacology, and Biology
Kappa 阿片受体的新型探针:化学、药理学和生物学
- 批准号:
9229013 - 财政年份:2016
- 资助金额:
$ 57.55万 - 项目类别:
Novel Probes of the Kappa Opioid Receptor: Chemistry, Pharmacology, and Biology
Kappa 阿片受体的新型探针:化学、药理学和生物学
- 批准号:
9113893 - 财政年份:2016
- 资助金额:
$ 57.55万 - 项目类别:
Molecular cancer therapy targeting HuR-ARE interaction
针对 HuR-ARE 相互作用的分子癌症治疗
- 批准号:
9297260 - 财政年份:2015
- 资助金额:
$ 57.55万 - 项目类别:
相似海外基金
Linking Epidermis and Mesophyll Signalling. Anatomy and Impact in Photosynthesis.
连接表皮和叶肉信号传导。
- 批准号:
EP/Z000882/1 - 财政年份:2024
- 资助金额:
$ 57.55万 - 项目类别:
Fellowship
Digging Deeper with AI: Canada-UK-US Partnership for Next-generation Plant Root Anatomy Segmentation
利用人工智能进行更深入的挖掘:加拿大、英国、美国合作开发下一代植物根部解剖分割
- 批准号:
BB/Y513908/1 - 财政年份:2024
- 资助金额:
$ 57.55万 - 项目类别:
Research Grant
Doctoral Dissertation Research: Social and ecological influences on brain anatomy
博士论文研究:社会和生态对大脑解剖学的影响
- 批准号:
2235348 - 财政年份:2023
- 资助金额:
$ 57.55万 - 项目类别:
Standard Grant
Simultaneous development of direct-view and video laryngoscopes based on the anatomy and physiology of the newborn
根据新生儿解剖生理同步开发直视喉镜和视频喉镜
- 批准号:
23K11917 - 财政年份:2023
- 资助金额:
$ 57.55万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Computational comparative anatomy: Translating between species in neuroscience
计算比较解剖学:神经科学中物种之间的翻译
- 批准号:
BB/X013227/1 - 财政年份:2023
- 资助金额:
$ 57.55万 - 项目类别:
Research Grant
computational models and analysis of the retinal anatomy and potentially physiology
视网膜解剖学和潜在生理学的计算模型和分析
- 批准号:
2825967 - 财政年份:2023
- 资助金额:
$ 57.55万 - 项目类别:
Studentship
Genetics of Extreme Phenotypes of OSA and Associated Upper Airway Anatomy
OSA 极端表型的遗传学及相关上呼吸道解剖学
- 批准号:
10555809 - 财政年份:2023
- 资助金额:
$ 57.55万 - 项目类别:
Development of a novel visualization, labeling, communication and tracking engine for human anatomy.
开发一种新颖的人体解剖学可视化、标签、通信和跟踪引擎。
- 批准号:
10761060 - 财政年份:2023
- 资助金额:
$ 57.55万 - 项目类别:
Understanding the functional anatomy of nociceptive spinal output neurons
了解伤害性脊髓输出神经元的功能解剖结构
- 批准号:
10751126 - 财政年份:2023
- 资助金额:
$ 57.55万 - 项目类别:
The Anatomy of Online Reviews: Evidence from the Steam Store
在线评论剖析:来自 Steam 商店的证据
- 批准号:
2872725 - 财政年份:2023
- 资助金额:
$ 57.55万 - 项目类别:
Studentship